Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ACAD |
---|---|---|
09:32 ET | 15176 | 15.06 |
09:34 ET | 1401 | 15.07 |
09:36 ET | 1618 | 15.07 |
09:38 ET | 8278 | 15.11 |
09:39 ET | 2100 | 15.14 |
09:41 ET | 1000 | 15.15 |
09:43 ET | 1000 | 15.18 |
09:45 ET | 2348 | 15.12 |
09:48 ET | 3530 | 15.09 |
09:50 ET | 1900 | 15.06 |
09:52 ET | 2714 | 15.06 |
09:54 ET | 1821 | 15.02 |
09:56 ET | 1400 | 15.01 |
09:57 ET | 7524 | 15.02 |
09:59 ET | 2300 | 15.06 |
10:01 ET | 1039 | 15.08 |
10:03 ET | 2001 | 15.08 |
10:06 ET | 1928 | 15.095 |
10:08 ET | 200 | 15.09 |
10:10 ET | 4365 | 15.1495 |
10:12 ET | 1551 | 15.13 |
10:14 ET | 300 | 15.13 |
10:15 ET | 4446 | 15.135 |
10:17 ET | 300 | 15.12 |
10:19 ET | 2200 | 15.12 |
10:21 ET | 2428 | 15.13 |
10:24 ET | 9327 | 15.21 |
10:26 ET | 3129 | 15.18 |
10:28 ET | 900 | 15.16 |
10:30 ET | 450 | 15.165 |
10:32 ET | 1400 | 15.19 |
10:33 ET | 1536 | 15.17 |
10:35 ET | 1100 | 15.16 |
10:37 ET | 3031 | 15.18 |
10:39 ET | 2865 | 15.17 |
10:42 ET | 1200 | 15.16 |
10:44 ET | 847 | 15.15 |
10:46 ET | 2054 | 15.155 |
10:48 ET | 3124 | 15.16 |
10:50 ET | 1252 | 15.18 |
10:51 ET | 3779 | 15.17 |
10:53 ET | 900 | 15.16 |
10:55 ET | 200 | 15.14 |
10:57 ET | 2861 | 15.15 |
11:00 ET | 1331 | 15.15 |
11:02 ET | 700 | 15.12 |
11:04 ET | 2760 | 15.12 |
11:06 ET | 6878 | 15.135 |
11:08 ET | 1807 | 15.115 |
11:09 ET | 150 | 15.125 |
11:11 ET | 1200 | 15.08 |
11:13 ET | 801 | 15.07 |
11:15 ET | 1198 | 15.08 |
11:18 ET | 1882 | 15.08 |
11:20 ET | 2173 | 15.06 |
11:22 ET | 3782 | 15.065 |
11:24 ET | 2662 | 15.08 |
11:26 ET | 3026 | 15.09 |
11:27 ET | 5530 | 15.1 |
11:29 ET | 1972 | 15.09 |
11:31 ET | 4819 | 15.1 |
11:33 ET | 1164 | 15.1 |
11:36 ET | 1150 | 15.09 |
11:38 ET | 1300 | 15.09 |
11:40 ET | 700 | 15.1 |
11:42 ET | 7250 | 15.11 |
11:44 ET | 100 | 15.1 |
11:45 ET | 300 | 15.09 |
11:47 ET | 3801 | 15.08 |
11:49 ET | 2992 | 15.06 |
11:51 ET | 696 | 15.05 |
11:54 ET | 400 | 15.05 |
11:56 ET | 4939 | 15.06 |
11:58 ET | 150 | 15.054 |
12:00 ET | 3619 | 15.08 |
12:02 ET | 1800 | 15.07 |
12:03 ET | 850 | 15.04 |
12:05 ET | 941 | 15.03 |
12:07 ET | 1144 | 15.04 |
12:09 ET | 100 | 15.035 |
12:12 ET | 1850 | 15.025 |
12:14 ET | 500 | 15.015 |
12:16 ET | 3438 | 15.01 |
12:18 ET | 7232 | 15.03 |
12:20 ET | 2061 | 15.025 |
12:21 ET | 1052 | 15.0247 |
12:23 ET | 3178 | 15.025 |
12:25 ET | 4404 | 15.025 |
12:27 ET | 7482 | 15 |
12:30 ET | 500 | 15 |
12:32 ET | 2199 | 15 |
12:34 ET | 466 | 14.99 |
12:36 ET | 2061 | 14.985 |
12:38 ET | 1366 | 14.98 |
12:39 ET | 245 | 14.975 |
12:43 ET | 1280 | 14.9799 |
12:45 ET | 1317 | 14.98 |
12:48 ET | 1434 | 14.97 |
12:50 ET | 5571 | 14.95 |
12:52 ET | 3472 | 14.935 |
12:54 ET | 1992 | 14.945 |
12:56 ET | 2456 | 14.945 |
12:57 ET | 1153 | 14.95 |
12:59 ET | 400 | 14.955 |
01:01 ET | 6472 | 14.98 |
01:03 ET | 5745 | 14.99 |
01:06 ET | 935 | 14.99 |
01:12 ET | 3049 | 14.975 |
01:15 ET | 1414 | 14.96 |
01:17 ET | 2000 | 14.98 |
01:19 ET | 674 | 14.975 |
01:21 ET | 2420 | 14.99 |
01:24 ET | 8784 | 14.97 |
01:26 ET | 800 | 14.955 |
01:28 ET | 5217 | 14.955 |
01:30 ET | 391 | 14.955 |
01:33 ET | 658 | 14.965 |
01:35 ET | 1406 | 14.955 |
01:37 ET | 1401 | 14.95 |
01:39 ET | 6362 | 14.92 |
01:42 ET | 5041 | 14.93 |
01:44 ET | 508 | 14.935 |
01:46 ET | 100 | 14.935 |
01:48 ET | 100 | 14.935 |
01:50 ET | 3304 | 14.91 |
01:51 ET | 1300 | 14.915 |
01:53 ET | 798 | 14.91 |
01:55 ET | 2688 | 14.905 |
01:57 ET | 9041 | 14.9 |
02:00 ET | 2912 | 14.93 |
02:02 ET | 2738 | 14.91 |
02:04 ET | 451 | 14.91 |
02:08 ET | 2274 | 14.925 |
02:09 ET | 2273 | 14.9 |
02:11 ET | 1141 | 14.91 |
02:13 ET | 499 | 14.91 |
02:15 ET | 100 | 14.91 |
02:18 ET | 100 | 14.92 |
02:20 ET | 4250 | 14.89 |
02:22 ET | 745 | 14.89 |
02:24 ET | 1700 | 14.9 |
02:26 ET | 900 | 14.91 |
02:27 ET | 1673 | 14.905 |
02:29 ET | 438 | 14.9 |
02:31 ET | 201 | 14.905 |
02:33 ET | 809 | 14.915 |
02:36 ET | 3907 | 14.92 |
02:38 ET | 1826 | 14.925 |
02:40 ET | 1413 | 14.905 |
02:42 ET | 400 | 14.91 |
02:44 ET | 200 | 14.905 |
02:45 ET | 1413 | 14.91 |
02:47 ET | 7231 | 14.945 |
02:49 ET | 1323 | 14.925 |
02:51 ET | 1463 | 14.945 |
02:54 ET | 221 | 14.945 |
02:56 ET | 400 | 14.945 |
02:58 ET | 5287 | 14.92 |
03:00 ET | 1268 | 14.9091 |
03:02 ET | 2607 | 14.895 |
03:03 ET | 1406 | 14.905 |
03:05 ET | 1492 | 14.91 |
03:07 ET | 4642 | 14.905 |
03:09 ET | 1850 | 14.895 |
03:12 ET | 225 | 14.895 |
03:14 ET | 7008 | 14.885 |
03:16 ET | 1729 | 14.9 |
03:18 ET | 5559 | 14.8691 |
03:20 ET | 1808 | 14.8601 |
03:21 ET | 550 | 14.865 |
03:23 ET | 1544 | 14.865 |
03:25 ET | 4496 | 14.862 |
03:27 ET | 2081 | 14.875 |
03:30 ET | 4650 | 14.885 |
03:32 ET | 2341 | 14.895 |
03:34 ET | 2147 | 14.885 |
03:36 ET | 3103 | 14.895 |
03:38 ET | 4921 | 14.9 |
03:39 ET | 4543 | 14.905 |
03:41 ET | 5339 | 14.905 |
03:43 ET | 3178 | 14.905 |
03:45 ET | 3960 | 14.9 |
03:48 ET | 7899 | 14.9 |
03:50 ET | 4659 | 14.925 |
03:52 ET | 16900 | 14.979 |
03:54 ET | 9643 | 14.955 |
03:56 ET | 19319 | 14.905 |
03:57 ET | 28983 | 14.895 |
03:59 ET | 312511 | 14.89 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
ACADIA Pharmaceuticals Inc | 2.5B | -1,157.0x | --- |
Azenta Inc | 2.7B | -19.7x | --- |
PTC Therapeutics Inc | 2.8B | -4.8x | --- |
Guardant Health Inc | 3.3B | -7.3x | --- |
Novavax Inc | 2.1B | -5.7x | --- |
Amicus Therapeutics Inc | 2.9B | -20.4x | --- |
Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and Antisense Oligonucleotide (ASO) Programs. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.6B |
---|---|
Revenue (TTM) | $813.8M |
Shares Outstanding | 165.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.37 |
EPS | $-0.01 |
Book Value | $2.62 |
P/E Ratio | -1,157.0x |
Price/Sales (TTM) | 3.1 |
Price/Cash Flow (TTM) | 285.4x |
Operating Margin | -0.56% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.